The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its ...
A high proportion of cases of congenital adrenal hyperplasia (CAH) are attributable to deficiency of 21-hydroxylase, which results in presentation of ambiguous genitalia at birth in girls but with no ...
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with ...
Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.
Hosted on MSN
Trump shows off 'gold card' as sales top $1 billion
President Donald Trump showcased the administration’s “Gold Card,” saying sales have topped $1.3 billion in just a few days, and described it as a “green card on steroids” and a new pathway for ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cadrenal Therapeutics has ...
Cadrenal Therapeutics (CVKD) acquired VLX-1005 and related 12-lipoxygenase assets from Veralox Therapeutics. The acquisition adds a late-stage, first-in-class drug candidate targeting a critical ...
Tait, J. F., Simpson, S. A., and Grundy, H. M., Lancet, i, 122 (1952). Simpson, S. A., Tait, J. F., and Bush, I. E., Lancet, ii, 226 (1952).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback